In the research world it is essential to share the achievements that are being made, not only with the rest of the research community, but also with the general public. The recent launched Oligofastx website makes this task easier by making available to everyone the latest news of the project. But let’s start from the beginning…
What is the Oligosfastx project?
The Oligofastx project aims to create a comprehensive platform to contribute to the development of oligonucleotide-based therapies in Spain for the treatment of rare diseases.
It is a biotechnological consortium led by SYLENTIS (PharmaMar Group) and involving, in addition to 53Biologics, other companies such as Nanovex Biotechnologies, ARTHEx Biotech, AptusBiotech, aptaTargets and NBD | Nostrum Biodiscovery.
What is the role of 53Biologics in the Oligofastx project?
Our main task in this project is to develop production systems based on biocatalytic methods. We are already working on it and we are confident our method will offer significant benefits in terms of selectivity, sustainability and cost reduction.
Stay up to date with all the latest news from Oligofastx website
If you are interested in rare disease research, you definetly have to take a look! In this new website (oligofast.com), there is information about the different rare diseases that could be treated with mRNA-based treatments. In addition to this information, there are content about the project, members and collaborators.
Partnering with the right CDMO to Advance mRNA Therapeutics
At 53Biologics we are working to offer support and guidance at every step of your mRNA project. Our service will guarantee a manufacturing supply on time, within budget and following the quality standards of your choice.
If you have an upcoming mRNA manufacturing project… Contact our team!